MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

myxoid liposarcoma

  • Home
  • myxoid liposarcoma
Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: Long-Term Results From the DOREMY Phase 2 Trial
Posted innews Oncology Radiology

Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: Long-Term Results From the DOREMY Phase 2 Trial

Posted by By MedXY 06/10/2026
Long-term follow-up from the DOREMY phase 2 trial shows that reduced-dose preoperative radiotherapy for localized myxoid liposarcoma achieved excellent local control with relatively low toxicity.
Read More
Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: Long-Term Results from the Phase 2 DOREMY Trial
Posted innews Oncology Radiology

Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: Long-Term Results from the Phase 2 DOREMY Trial

Posted by By MedXY 06/10/2026
A long-term phase 2 trial found that reduced-dose preoperative radiotherapy followed by surgery provided excellent local control and acceptable toxicity in localized myxoid liposarcoma.
Read More
Reduced Preoperative Radiotherapy to 36 Gy Maintains Excellent Long-Term Local Control in Myxoid Liposarcoma
Posted innews Oncology Radiology

Reduced Preoperative Radiotherapy to 36 Gy Maintains Excellent Long-Term Local Control in Myxoid Liposarcoma

Posted by By MedXY 05/19/2026
Long-term phase 2 data suggest that 36 Gy preoperative radiotherapy for localized myxoid liposarcoma preserves excellent local control while limiting wound and late toxic effects.
Read More
  • Reevaluating Sentinel Lymph Node Biopsy in Older Women with cT2N0 HR+/HER2- Breast Cancer: Limited Impact on Treatment Decisions
  • Immunotherapy-Induced Endocrine Dysfunction in Gynecologic Oncology: Clinical Insights from a Retrospective Cohort Study
  • Serum GLP-1 as a Novel Biomarker for Endometrial Cancer Detection in Obese Women
  • Ten Years of Uterus Transplantation in the US: Surgical Success, Reproductive Milestones, and Child Development Outcomes
  • Improving Pregnancy Outcomes Through Enhanced Prenatal Care Data and Metrics: A Comprehensive Evidence Synthesis
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top